Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.

[1]  Jiaofeng Huang,et al.  Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[2]  H. Grønbæk,et al.  The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. , 2020, Trends in genetics : TIG.

[3]  H. Tilg,et al.  From NAFLD to MAFLD: when pathophysiology succeeds , 2020, Nature Reviews Gastroenterology & Hepatology.

[4]  Anoop Misra,et al.  From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. , 2020, Diabetes & metabolic syndrome.

[5]  S. Pelusi,et al.  Redefining fatty liver disease classification in 2020 , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[6]  N. Chavez-Tapia,et al.  Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease , 2020, Annals of Hepatology.

[7]  The Lancet Gastroenterology & Hepatology.  Redefining non-alcoholic fatty liver disease: what's in a name? , 2020, The lancet. Gastroenterology & hepatology.

[8]  S. Bollipo,et al.  What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’ , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[9]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[10]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[11]  H. Janssen,et al.  Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B , 2020, Hepatology.

[12]  G. Marchesini,et al.  Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation , 2020, Hepatology.

[13]  F. Hasan,et al.  The Burden and Clinical Care Pathways of Nonalcoholic Steatohepatitis in the Middle East , 2019, Clinical liver disease.

[14]  S. Alavian,et al.  The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017 , 2019, Clinical liver disease.

[15]  E. Benjamin,et al.  Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  F. Azizi,et al.  Metabolic health in the Middle East and north Africa. , 2019, The lancet. Diabetes & endocrinology.

[17]  J. George,et al.  Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology , 2019, Nature Reviews Gastroenterology & Hepatology.

[18]  A. Eshraghian,et al.  Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Iranian Patients. , 2019, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[19]  A. Sanyal,et al.  Toward More Accurate Nomenclature for Fatty Liver Diseases , 2019, Gastroenterology.

[20]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[21]  J. Schattenberg,et al.  The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs , 2019, Front. Med..

[22]  Eda Kaya,et al.  Türkiye'de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi , 2019 .

[23]  I. Waked,et al.  One step closer to elimination of hepatitis C in Egypt. , 2018, The lancet. Gastroenterology & hepatology.

[24]  Gretchen A Stevens,et al.  Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. , 2018, The Lancet. Global health.

[25]  M. Manns,et al.  The Lancet–EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities , 2018, The Lancet.

[26]  F. Sanai,et al.  Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030 , 2018, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[27]  G. Moradi,et al.  Prevalence of non-alcoholic Fatty Liver Disease in Kurdistan province, Iran, 2013 – 2014: A Population Based Study , 2018 .

[28]  M. Eslam,et al.  Genetics and epigenetics of NAFLD and NASH: Clinical impact. , 2018, Journal of hepatology.

[29]  Nizal Sarrafzadegan,et al.  Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden , 2018, Nature Reviews Cardiology.

[30]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[31]  V. Wong,et al.  Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment , 2018, Journal of gastroenterology and hepatology.

[32]  B. Neuschwander‐Tetri,et al.  Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science , 2017, Hepatology.

[33]  G. Garas,et al.  Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma , 2017, Hepatology communications.

[34]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[35]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[36]  Gemma A. Williams,et al.  Obesity in Middle East , 2016 .

[37]  OstovanehMohammad Reza,et al.  Nonalcoholic Fatty Liver: The Association with Metabolic Abnormalities, Body Mass Index and Central Obesity—A Population-Based Study , 2015 .

[38]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[39]  E. El-Ghitany,et al.  Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt. , 2014, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[40]  A. McCullough,et al.  The impact of obesity and metabolic syndrome on alcoholic liver disease. , 2014, Clinics in liver disease.

[41]  M. Volk,et al.  Consequences of Perceived Stigma Among Patients with Cirrhosis , 2014, Digestive Diseases and Sciences.

[42]  F. Azizi,et al.  Dietary trends in the Middle East and North Africa: an ecological study (1961 to 2007) , 2012, Public Health Nutrition.

[43]  I. Ďuriš,et al.  Nonalcoholic Fatty Liver Disease of Two Ethnic Groups in Kuwait: Comparison of Prevalence and Risk Factors Internal Medicine And , 2022 .

[44]  B. Fromenty,et al.  Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.

[45]  N. Dalkey.  STUDIES IN THE QUALITY OF LIFE; DELPHI AND DECISION-MAKING. , 1972 .